EQRx Aims To Upend Industry’s Pricing Model, With Me-Too Drugs

 
• By Jessica Merrill

With a $200m series A financing and an illustrious founding team, including Alexis Borisy and Peter Bach, EQRx plans to develop cheap me-too drugs. The start-up could pose a new threat to big pharma.

Thinking big business concept as a large rocket blasting through the smoke of a group of jet air planes as a financial metaphor for corporate winner as a 3D render.
EEQRx hopes to disrupt industry's business as usual pricing model • Source: Shutterstock

More from Start-Ups & SMEs

More from Business